ReviewFrontiers in pain research (Lausanne, Switzerland)2026
Is histamine intolerance a treatable subtype of fibromyalgia? evidence and clinical implications-narrative review.
Review in Frontiers in pain research (Lausanne, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fibromyalgia affects 2%-8% of the global population with suboptimal treatment outcomes. Emerging evidence suggests histamine intolerance, mediated by diamine oxidase (DAO) deficiency, may contribute to fibromyalgia pathophysiology in specific patient subgroups. Methods: We conducted a comprehensive narrative review of literature published 2000-2025, examining genetic polymorphisms, biochemical markers, and clinical studies investigating relationships between histamine intolerance, DAO deficiency, and fibromyalgia. Studies included genetic association analyses, randomized controlled trials, and population-based observational research. Results: Key findings revealed 74.5% prevalence of DAO deficiency-associated genetic variants in fibromyalgia patients vs. 66% in general population ( Conclusion: Current evidence supports systematic histamine intolerance assessment in fibromyalgia patients presenting with gastrointestinal symptoms, chronic pruritus, or treatment resistance. This review provides a practical clinical framework for identifying and managing this potentially treatable fibromyalgia subtype, though larger multicenter replication studies are needed to confirm findings and establish standardized diagnostic protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.